Skip to main content
Signal8
Launch Terminal

Eledon Pharmaceuticals, Inc. (ELDN)

Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc.

NASDAQ:ELDNHealthcare
-8.88%$2.77
AH$2.93+5.68%vs close
Mkt Cap$225.09M
Float80.98M
O/S81.26M
Vol
$ Vol
RVOL
Inst Own57.7%
SI9.8%
Earnings
Dilution
Eledon Pharmaceuticals, Inc. logoNASDAQ:ELDN$2.77-8.88%
Phase Distribution
10 lead-sponsored trials·2 active·5 completed
Phase 13
Phase 1/22
Phase 24
Phase 31
(2 more as collaborator)
Status Overview
Not yet recruiting1
Recruiting2
Completed5
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Not yet recruiting

    Study of Tegoprubart Efficacy and Safety Compared With Tacrolimus in Kidney Transplantation

    Tegoprubart, Tacrolimus

    Kidney Transplant Rejection

    Enrollment
    620
    Start
    Oct 2026est.
    Primary Completion
    Mar 2029est.
    Completion
    Mar 2033est.
    NCT07835581
  • Phase 2
    Completed

    A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months

    Amoxicillin-clavulanate

    Acute Otitis Media

    Enrollment
    103
    Start
    Feb 2019
    Primary Completion
    Mar 2020
    Completion
    Mar 2020
    NCT03818815
  • Phase 2
    Terminated

    Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

    AT-1501

    IgA Nephropathy, IgAN

    Enrollment
    24
    Start
    Mar 2022
    Primary Completion
    Jul 2023
    Completion
    Jul 2023
    NCT05125068
  • Phase 2
    Completed

    Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

    AT-1501, Tacrolimus

    Kidney Transplant Rejection

    Enrollment
    127
    Start
    Aug 2023
    Primary Completion
    Sep 2025
    Completion
    Sep 2025
    NCT05983770
  • Phase 2
    Enrolling by invitation

    Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

    AT-1501, Tacrolimus

    Kidney Transplant Rejection

    Enrollment
    132
    Start
    Oct 2023
    Primary Completion
    Dec 2029est.
    Completion
    Dec 2029est.
    NCT06126380
  • Phase 1/2
    Recruiting

    Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

    AT-1501

    Prevention of Rejection in Kidney Transplant

    Enrollment
    48
    Start
    Feb 2022
    Primary Completion
    Jan 2027est.
    Completion
    Jan 2027est.
    NCT05027906
  • Phase 1/2
    Withdrawn

    Safety, Tolerability, and Efficacy of Immunomodulation With AT-1501 in Combination With Transplanted Islet Cells in Adults With Brittle T1D

    AT-1501 IV Infusion, Isolated cadaveric islet cells

    Brittle Type 1 Diabetes Mellitus

    Enrollment
    0
    Start
    Sep 2022
    Primary Completion
    Aug 2024est.
    Completion
    Aug 2028est.
    NCT05480657
  • Phase 1
    Completed

    Evaluation of Safety of Repeated Doses of OP0201 Metered Dose Inhaler Compared to Placebo in Healthy Adult Volunteers

    Drug: OP0201, Drug: Placebo

    Healthy Adult Volunteers

    Enrollment
    30
    Start
    Nov 2018
    Primary Completion
    Mar 2019
    Completion
    Mar 2019
    NCT03748758
  • Phase 1
    Completed

    Evaluation of Safety and Reduction of Ear Pain in Adults With Acute Otitis Media and Reduction of Ear Pain in Adults With Acute Otitis Media

    Drug: OP0201 20mg, Drug: Placebo 0mg

    Acute Otitis Media

    Enrollment
    24
    Start
    Jan 2019
    Primary Completion
    Jan 2019
    Completion
    Jan 2019
    NCT03766373
  • Phase 1
    Completed

    Evaluation of Safety and Pharmacodynamics of OP0201 Compared to Placebo in Healthy Adults

    Drug:OP0201, Drug: Placebo

    Healthy Adults

    Enrollment
    17
    Start
    Feb 2019
    Primary Completion
    Mar 2019
    Completion
    Mar 2019
    NCT03828149
Search ClinicalTrials.gov for “Eledon Pharmaceuticals”